Literature DB >> 9225641

Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.

M Akerlund1.   

Abstract

BACKGROUND: The risk of thromboembolic events related to the ethinyl estradiol (EE) dose in oral contraceptive (OC) pills has led to a further dose reduction.
METHODS: An OC pill with 150 micrograms desogestrel combined with only 20 micrograms EE was compared with a pill containing the same dose of desogestrel but 30 micrograms of EE in a Scandinavian multicentre study with follow-up visits after 3, 6 and 12 months.
RESULTS: In almost 5,000 cycles with each pill the numbers of pregnancies due to method failure with the lower and higher EE dose pills were 0 and 2, respectively. Irregular bleedings were slightly more common with the lower EE dose, but tended to decrease over the year of study. Other side effects were uncommon. Regarding metabolic effects, both pills tended to raise the plasma HDL level and the lower EE dose pill also reduced LDL. Free testosterone was reduced by two-thirds with both pills, showing beneficial effects on acne.
CONCLUSIONS: It is concluded that both these pills are reliable and safe, but that many women would accept a slightly greater risk of irregular bleeding with the 20 micrograms EE dose pill in exchange for a reduction in potential risk related to the estrogenic component of OC pills.

Entities:  

Keywords:  Biology; Bleeding; Clinical Research; Contraception; Contraceptive Agents, Estrogen--administraction and dosage; Contraceptive Agents, Estrogen--side effects; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin; Contraceptive Agents--administraction and dosage; Contraceptive Agents--side effects; Contraceptive Effectiveness; Contraceptive Methods; Desogestrel; Developed Countries; Diseases; Ethinyl Estradiol--administraction and dosage; Ethinyl Estradiol--side effects; Europe; Evaluation; Family Planning; Metabolic Effects; Northern Europe; Oral Contraceptives; Oral Contraceptives, Low-dose; Physiology; Research Methodology; Research Report; Risk Assessment; Scandinavia; Signs And Symptoms; Sweden

Mesh:

Substances:

Year:  1997        PMID: 9225641

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand Suppl        ISSN: 0300-8835


  3 in total

Review 1.  20 µg versus >20 µg estrogen combined oral contraceptives for contraception.

Authors:  Maria F Gallo; Kavita Nanda; David A Grimes; Laureen M Lopez; Kenneth F Schulz
Journal:  Cochrane Database Syst Rev       Date:  2013-08-01

2.  Safety data and beneficial effects of the combined oral contraceptive ethinylestradiol 0.03 mg/chlormadinone acetate 2 mg (Belara®): a 13-cycle, observational study in routine clinical practice.

Authors:  Daphnee S Pushparajah; Petra Röhm; Kornelia Höschen; Dagmar Albers; Christina Nowack
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  Effect of injectable and oral contraceptives on serum lipids.

Authors:  Abbey B Berenson; Mahbubur Rahman; Gregg Wilkinson
Journal:  Obstet Gynecol       Date:  2009-10       Impact factor: 7.661

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.